Table 4.
Association of Haplotype Diversity with OS in All Patients
| Haplotype* | Frequency | MST | HR† (95% CI) | P |
|---|---|---|---|---|
| IGF2R | ||||
| ACAC | 0.3287 | 18.7 | 1.0 | |
| GTGC | 0.0577 | 16.5 | 1.28 (1.00–1.64) | 0.05 |
| IGFBP3 | ||||
| CGAT | 0.3748 | 16.3 | 1.0 | |
| ACAT | 0.2825 | 17.7 | 0.87 (0.77–0.99) | 0.04 |
| IGFBP5 | ||||
| CA | 0.538 | 17.5 | 1.0 | |
| TC | 0.01 | 5.0 | 2.73 (1.02–7.34) | 0.046 |
| IRS1 | ||||
| CGGG | 0.8243 | 18.1 | 1.0 | |
| CAGG | 0.072 | 10.3 | 1.41 (1.13–1.76) | 0.002 |
| GGGG | 0.033 | 13.3 | 1.76 (1.28–2.42) | <0.001 |
| IRS2 | ||||
| GACGTC | 0.2399 | 18.5 | 1.0 | |
| AGCGCT | 0.0595 | 14.3 | 1.35 (1.02–1.77) | 0.03 |
| GGCGTC | 0.0439 | 14.7 | 1.43 (1.04–1.96) | 0.03 |
| AGCGCC | 0.0405 | 14.3 | 1.67 (1.21–2.29) | 0.001 |
MST, median survival time (months); CI, confidence interval; HR: hazard ratio; CA19-9, carbohydrate antigen 19-9 HR values were from multivariate Cox regression models including sex, race, clinical stage, tumor resection, CA 19-9, biochemical index and performance status.
*
Haplotype of IGF2R T713T, L2222L, S350S, L252V; IGFBP3 -202A>C, A32G, H164P, Ex5-411A>T; IGFBP5 R138W, IVS1-6727A>C; IRS1 IVS1+4315C>G, G972R, IVS1-10949G>A, A512P; IRS2 Ex2+750A>G, G1057D, P829P, IVS1+2498G>A, IVS1+5687T>C, IVS1+166T>C. Those haplotypes with P>0.05 in Cox regression models were not shown.